Source comparison
BPC-157 vs Cartalax: Side-by-Side Research Comparison
The following table contrasts the core research parameters that differentiate BPC-157 and Cartalax in experimental design. Use this to determine which peptide aligns with your study's mechanistic focus. Primary Mechanism Angiogenesis via VEGF upregulation, nit
This comparison does not assign a generated winner or score.
- The following table contrasts the core research parameters that differentiate BPC-157 and Cartalax in experimental design. Use this to determine which peptide aligns with your study's mechanistic focus.
- Primary Mechanism
- Angiogenesis via VEGF upregulation, nitric oxide pathway modulation
- Gene expression regulation through chromatin interaction
- BPC-157 for structural repair; Cartalax for cellular aging
- Research Application
- Tissue injury models, GI ulcer studies, musculoskeletal repair
- Cellular senescence, longevity studies, age-related decline
- Non-overlapping. Select based on damage type vs aging focus
- Typical Dosing Range
- 200–500 mcg daily (rodent models, scaled to body weight)
- 10–20 mcg every 2–3 days in 10–20 day cycles
- BPC-157 higher dose, continuous; Cartalax lower dose, cyclical
- Study Duration
- 2–8 weeks (acute injury healing timelines)
- Months to years (lifespan and aging studies)
- BPC-157 shorter-term; Cartalax requires extended observation
- Success Endpoints
- Tensile strength, healing rate, lesion size, inflammatory markers
- Protein synthesis rate, antioxidant enzyme expression, mitochondrial function
- Structural metrics vs molecular/systemic markers
- Reconstitution Stability
- Stable 28+ days at 2–8°C post-reconstitution
- Use within 14–21 days post-reconstitution (shorter stability window)
- BPC-157 tolerates longer storage; Cartalax requires tighter inventory control